The bottleneck in computational biology is no longer the algorithm. It is the wet lab bench. A protein design AI can generate thousands of promising candidates in minutes, but validating a single one traditionally requires weeks of manual pipetting, cell culture, and assay work. Adaptyv, a Lausanne-based startup, is building the machine to close that loop. Its platform is an automated, AI-native wet lab that takes a digital protein sequence and returns experimental validation data, aiming to turn biology into a high-throughput engineering discipline.
The Protein Printer
At its core, Adaptyv is a service that automates the physical steps of protein testing. A customer, which could be a pharmaceutical giant like Roche or an AI research lab like Anthropic, submits a digital protein sequence via an API. The platform then handles DNA synthesis, cell-free protein expression, and measurement through automated workflows that utilize robotics and microfluidics [Adaptyv Bio Blog, Unknown]. The company brought DNA synthesis in-house to control this critical path [Wowtale, August 2026]. The output is not a physical vial of protein, but structured data on expression levels, stability, or binding affinity,the exact metrics a computational team needs to refine its models. The bet is that by making validation faster and cheaper, you can test more designs, learn faster, and materially improve success rates. The company reports it boosted protein success rates from an industry-typical 2.5% to 13% in a two-month period for over 30 pharma and biotech teams [Reto Gurtner - LinkedIn, Retrieved 2026].
The Integration Wedge
Adaptyv's initial wedge into the market is developer experience for computational biologists. Instead of selling a monolithic enterprise platform, it built a public API. This API is now integrated with a suite of popular protein design and lab notebook tools, including Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling [Wowtale, August 2026]. For a team already designing proteins in Cradle or managing experiments in Benchling, sending a batch of candidates to Adaptyv for testing can be a few lines of code. This approach lowers the adoption barrier and positions Adaptyv as a utility layer rather than a disruptive workflow change. It also creates a clear data flywheel: more experiments run through the platform generate more training data, which can be used to improve the company's own predictive models and assay designs.
Funding and Traction
The company, founded in 2021 by Julian Englert and Daniel Nakhaee-Zadeh Gutierrez after they met at EPFL, has raised approximately $50 million to date [adaptyvbio.com/team]. Its recent $40 million Series A in August 2026 was led by Highland Europe, with participation from existing investors ACE Ventures, byFounders, and Y Combinator [Wowtale, August 2026]. The capital is earmarked for scaling its automated lab operations. Traction metrics show a company moving from prototype to scale. Adaptyv reports serving over 100 customers, a list that includes biotech AI labs like Chai Discovery and Boltz, alongside pharmaceutical giants Roche and Novo Nordisk [GGBa, Unknown]. It has tested over 10,000 proteins since its beta launch [BioAlps, Unknown].
2021 Pre-seed | 2.75 | M USD
2024 Seed | 8 | M USD
2026 Series A | 40 | M USD
The Technical Breakdown
From an infrastructure perspective, Adaptyv's stack is a hybrid of hardware automation, synthetic biology, and software orchestration. The key technical components are its in-house DNA synthesis, which removes a major external dependency and latency, and its use of cell-free expression systems. Cell-free reactions, which produce proteins without living cells, are faster and more amenable to miniaturization in microfluidic chips than traditional fermentation. The platform's software layer must then schedule robotic arms, manage reagent inventories, and quality-control the resulting data streams. The reported 5x increase in lab throughput over the past year points to significant optimization in this orchestration layer [Dealroom News, Unknown]. The real technical moat may be in the proprietary datasets generated from running thousands of parallel experiments, which could train models to predict experimental outcomes and guide more efficient testing strategies.
Scaling the Foundry
The primary risk for Adaptyv is operational complexity at scale. Running a high-throughput, automated wet lab is a capital-intensive business with physical constraints. Reagent supply chains can be fragile. Each new type of protein assay or measurement may require reconfiguring hardware or developing new chemical protocols, which doesn't scale like software. Furthermore, as the company grows, it must balance serving a diverse customer base,from AI startups testing novel scaffolds to pharma companies optimizing known enzymes,without becoming a custom development shop for each. Its answer appears to be a focus on platformization and the API, letting customers self-serve within defined parameters. The long-term question is whether Adaptyv can maintain the throughput and cost advantages that make it indispensable as large customers inevitably build internal automation capabilities. Its current lead, cemented by this fresh $40 million, gives it a window to become the default protein foundry before that happens.
Sources
- [Wowtale, August 2026] Adaptyv Bio Raises $40M to Automate the Lab That Validates AI-Designed Proteins | https://en.wowtale.net/2026/08/29/234934
- [Adaptyv Bio Blog, Unknown] Company blog post on platform launch and success rates | https://www.adaptyvbio.com/blog/launch
- [Reto Gurtner - LinkedIn, Retrieved 2026] LinkedIn post on Adaptyv's success rate improvement | https://www.linkedin.com/in/retogurtner
- [GGBa, Unknown] Article on Adaptyv's customer onboarding | https://www.ggba.com
- [BioAlps, Unknown] BioAlps profile on Adaptyv's protein testing volume | https://www.bioalps.ch
- [Dealroom News, Unknown] Dealroom news item on Adaptyv's growth | https://www.dealroom.co
- [adaptyvbio.com/team] Adaptyv company team page | https://www.adaptyvbio.com/team
- [ACE Ventures, Retrieved 2026] Fireside Chat with Julian Englert, Co-Founder of Adaptyv | https://aceandcompany.com/news/fireside-chat-julian-englert-adaptyv